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Abstract
Background: Lewis y antigen is difucosylated oligosaccharide and is carried by glycoconjugates at
cell surface. Elevated expression of Lewis y has been found in 75% of ovarian tumor, and the high
expression level is correlated to the tumor's pathological staging and prognosis. This study was to
investigate the effect and the possible mechanism of Lewis y on the proliferation of human ovarian
cancer cells.
Methods: We constructed a plasmid encoding α1,2-fucosyltransferase (α1,2-FT) gene and then
transfected it into ovarian carcinoma-derived RMG-I cells with lowest Lewis y antigen expression
level. Effect of Lewis y on cell proliferation was assessed after transfection. Changes in cell survival
and signal transduction were evaluated after α-L-fucosidase, anti-Lewis y antibody and
phosphatidylinositol 3-kinase (PI3K) inhibitor treatment.
Results: Our results showed that the levels of α1,2-FT gene and Lewis y increased significantly
after transfection. The cell proliferation of ovarian carcinoma-derived RMG-I cells sped up as the
Lewis y antigen was increased. Both of α-L-fucosidase and anti-Lewis y antibody inhibited the cell
proliferation. The phosphorylation level of Akt was apparently elevated in Lewis y-overexpressing
cells and the inhibitor of PI3K, LY294002, dramatically inhibited the growth of Lewis y-
overexpressing cells. In addition, the phosphorylation intensity and difference in phosphorylation
intensity between cells with different expression of α1,2-FT were attenuated significantly by the
monoantibody to Lewis y and by the PI3K inhibitor LY294002.
Conclusions: Increased expression of Lewis y antigen plays an important role in promoting cell
proliferation through activating PI3K/Akt signaling pathway in ovarian carcinoma-derived RMG-I
cells. Inhibition of Lewis y expression may provide a new therapeutic approach for Lewis y positive
ovarian cancer.
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Background
Lewis y antigen is carried by glycoconjugates (glycopro-
teins and glycolipids) at cell surface. It is an oligosaccha-
ride with two fucoses, and its chemical structure is Fucα1
→ 2Galβ1 → 4 [Fucα1 → 3]GlcNAcβ1 → R, belonging to
the A, B, H, Lewis blood group antigens family with spe-
cific fucosylation of the terminal end of carbohydrate
structure catalyzed by the α1,2-fucosyltransferase [1,2].
The expression of Lewis y antigen primarily occurs during
the embryogenesis period. Under physiologic conditions,
its expression in adults is limited on the surface of granu-
locytes and epithelium [3]. However, elevated expression
of Lewis y has been found in 70-90% of the human carci-
nomas of epithelial cell origin, including breast, ovary,
prostate, colon cancers, and the high expression level is
correlated to the tumor's pathological staging and prog-
nosis [4-6]. It has been reported that the Lewis y antigen
was expressed on a number of different molecular carriers,
including 2 major ovarian cancer antigens (CA125 and
MUC-1), suggesting the high incidence of Lewis y in ovar-
ian cancer [7].
We have established the stable ovarian cancer cell line
with high expression of Lewis y, RMG-I-H, through gene
transfection technique to introduce the gene of human
α1,2-fucosyltransferase (α1,2-FT) into the ovarian cancer
cell line RMG-I in our previous works. We found that the
RMG-I-H cells become highly tolerant to the anti-tumor
drugs, 5-fluorouracil, carboplatin [8,9]. It suggested that
the Lewis y antigen possessed the function of boosting the
survival ability of ovarian cancer cells.
Activation of the PI3K pathway supports survival and pro-
liferation of multiple cell lineages [10]. PI3K activation
results in the localized increase of phosphorylated lipid
second messengers at the plasma membrane. Key signal-
ing intermediates are then recruited to the phosphor-
ylated lipids via specialized lipid-binding domains,
pleckstrin homology (PH) domains, and are themselves
activated to initiate further signaling events [11,12]. One
key effector molecule that is activated in this manner is the
serine/threonine kinase Akt, which, when localized to
products of PI3K activation, is able to phosphorylate mul-
tiple downstream substrates that mediate cell growth, sur-
vival, and metabolism [13-15]. Studies found that soluble
Lewis y antigen (4A11) or its glucose analog, H-2 g, effect
angiogenesis by inducing VEGF expression and signaling
through PI3K pathway in the angiogenesis-rich rheuma-
toid arthritis [16].
Here we report that the cell proliferation of ovarian cancer
cell line RMG-I sped up as the Lewis y antigen was
increased. The phosphorylation level of Akt was appar-
ently elevated in Lewis y-overexpressing cells. The inhibi-
tor of PI3K, LY294002, dramatically inhibited the growth
of Lewis y-overexpressing cells. Taken together, Lewis y
antigen stimulates the growth of ovarian cancer cells
through activating PI3K/Akt signal-transduction pathway.
Potential treatment strategies through the inhibition of
PI3K signaling pathway to target Lewis y signals may pro-
vide a useful approach for therapy of ovarian tumor
growth.
Methods
Materials
The human ovarian cancer cell line, RMG-I, which was
established from the tissues of human ovarian clear cell
carcinoma, donated by Professor Iwamori Masao of
Tokyo University of Japan. The following reagents were
purchased from commercial sources: expression vector
pcDNA3.1(-) and a TA cloning kit from Invitrogen (San
Diego, CA, USA); E. coli (competent cells) JM109 from
Toyobo (Tokyo, Japan); restriction endonucleases,
BamHI, EcoRI, and G418  (geneticin) from Gibco; cell
transfection and NucleoBond plasmid kits from GE
Healthcare (Piscataway, NJ, USA); AmpliTaq Gold™ and a
Bigdye™ terminator cycle sequencing ready reaction kit
from Perkin-Elmer/Applied Biosystems (Foster City, CA,
USA); DMEM and fetal bovine serum (FBS) from Hyclone
(Logan, UT, USA); trypsin, ethylenediamine tetraacetic
acid (EDTA), dimethyl sulfoxide (DMSO) and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) from Amresco (Solon, OH, USA); SABC test kit
from Boshide Biotech Co (Wuhan, China); α-L-fucosidase
and methylene blue from Sigma (St. Louis, MO); PI3K
inhibitor LY294002 from Promega (Madison, WI); prim-
ers and Reverse Transcription Polymerase Chain Reaction
(RT-PCR) reagents are products of TaKaRa Biotechnology
Co. Ltd (Dalian, China); mouse anti-human Lewis y mon-
oclonal antibody from Abcam (UK); rabbit anti-human
IgM monoclonal antibody, PCNA and β-actin from Santa
Cruz Biotechnology (Santa Cruz, CA, USA); Akt and p-Akt
from Cell Signaling Technology, Inc. (Beverly, MA, USA);
protein content in cell lysates was measured by the BCA
method (Beyotime, China).
Cell culture
Cells were cultured in DMEM supplemented with 10%
FBS at 37°C under 5% CO2 in humidified air.
Construction of plasmid and generation of stably 
transfected cell lines
The human α1,2-fucosyltransferase gene (FUT-1) was
amplified by PCR with human leukocyte genomic DNA as
a template and primers according to the human FUT-1
gene sequence (GenBank Accession Number: M35531),
sense primer, 5'-CATGTGGCTCCGGAGCCATCGTC-3',
and antisense primer, 5'-GCTCTCAAGGCTTAGCCAAT-
GTCC-3', under the following conditions: denaturation at
94°C for 9 min, followed by 25 cycles of 94°C, 1 min,Journal of Experimental & Clinical Cancer Research 2009, 28:154 http://www.jeccr.com/content/28/1/154
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65°C, 1.5 min, and 72°C, 2 min, and then extension at
72°C for 10 min. The PCR products were ligated into the
pCR2.1 vector to clone FUT-1 gene, and its DNA sequence
was determined by means of the dideoxynucleotide
chain-termination method with the BigDye terminator
cycle sequenceing ready reaction kit and a DNA sequencer
(ABI Genetic Analyzer; Perkin-Elmer/Applied Biosys-
tems). Then the FUT-1 gene in pCR2.1 was cut out by
digestion with restriction enzymes, BamHI and EcoRI,
and ligated into the BamHI and EcoRI sites of the
pcDNA3.1 vector (pcDNA3.1-hFUT). pcDNA3.1-hFUT
and the vector alone were transfected into RMG-I cells
with a vector transfection kit, according to the instructions
for the kit to establish RMG-I-H and RMG-I-pcDNA3.1
cells, respectively. The resultant transfectants were initially
selected by cultivation with medium containing an
aminoglycoside antibiotic, G418, at 400 μg/ml concentra-
tion, and were maintained at 200 μg/ml for 15 days.
Determination of α1,2-FT mRNA with semi-quantitative 
RT-PCR
Total RNA was extracted from the transfected and control
cells using Trizol reagent. The cDNA was synthesized
using Takara RNA PCR Kit and was used as a template for
PCR analysis. The primer for α1,2-FT was F: 5'-GACTGT-
GGATCTGCCACCTG-3', R: 5'-GAAAGCTGTCTTGAT-
GGATATGGAG-3' (fragment size, 131 bp). The primer for
β-actin was F: 5'-GGACTTCGAGCAAGAGATGG-3', R: 5'-
ACATCTGCTGGAAGGTGGAC-3' (fragment size, 404 bp).
The cDNA was subjected to denaturation at 94°C for 5
min, followed by 30 cycles (94°C for 60 s, 65°C for 60 s,
and 72°C for 60 s) of PCR and incubated at 5 minutes of
72°C. Then 10 μl of amplified products were detected by
2% agarose gel electrophoresis. The amplified DNA bands
were scanned and analyzed with nih image software The
quantitative data were obtained by the intensity ratios of
α1,2-FT/β-actin band.
Analysis the effect of Lewis y antigen on cell proliferation
Cells (2 × 103/well) were planted in 96-well plates. MTT
assay was used to detect cell proliferation for consecutive
7 days. In brief, MTT was added to the culture medium to
yield a final MTT concentration of 0.5 mg/ml and the
incubation was continued for 4 h at 37°C. The cell lysates
were dissolved with DMSO at room temperature for 10
min. Results were obtained by measuring the absorbance
at a wavelength of 490 nm. The test was repeated for three
times.
The removal of fucosyl residues on cell surface
The RMG-I-H and RMG-I (1 × 105/ml) cells, were sepa-
rately suspended in the solution of DMEM of pH 6.0,
which included α-L-fucosidase (100 mU/ml). The labora-
tory requirement for removal of fucosyl residue followed
the Sasak method [17], where the control sample was only
added with DMEM of pH 6.0, excluding the addition of
enzyme. The solution was incubated for 1 h at 37°C, and
washed twice with DMEM of pH 7.25, before measure-
ment. The enzyme concentration and incubation time
were already determined before the experiment, and all
fucosyl residues were mostly verified to be removed. The
experimental group were named as RMG-I-H-A and RMG-
I-A, respectively.
Analysis the effect of α-L-fucosidase on cell proliferation
The cells before and after the process by α-L-fucosidase as
above mentioned were seeded into 96-well plate at 3000
cells/well, and cell number was examined by MTT assay in
triplicates for consecutive 7 days to detect cell prolifera-
tion. The test was repeated for three times.
Colony formation test
Bottom agarose (0.7%) in DMEM was cast on 24-well
plates. The cells before and after the process by α-L-fucosi-
dase were mixed in 0.3% agarose in DMEM containing
10% FBS at 37°C and plated over the bottom agarose. The
inoculated plates were incubated for 14 days and the
number of cell clones with more than 50 cells was
counted under microscope in each well (clone formation
rate = number of clones in each dish/1000). Three redu-
plicate wells were used from each clone. Cell colonies
were then fixed and stained with 0.5% methylene blue in
ethanol. All colonies visible by eye were counted sepa-
rately for each sample and evaluated their clone forma-
tion rates.
Analysis the effect of anti-Lewis y antibody on cell 
proliferation
The RMG-I-H and RMG-I cells were separately added to
96-well plate at 3000 cells/well, after incubated for 2 h at
37°C in a humidifed atmosphere containing 5% CO2,
Lewis y antibody (20 μg/ml) was added to wells as the
experimental group, named as RMG-I-H-a and RMG-I-a,
respectively; while rabbit anti-human IgM antibody of the
same concentration was added as the control group,
named as RMG-I-H-C and RMG-I-C, respectively. The cell
number was examined by MTT assay in triplicates for con-
secutive 7 days to detect cell proliferation. The test was
repeated for three times.
Analysis the effects of the PI3K inhibitor LY294002 on cell 
proliferation
The RMG-I-H and RMG-I cells were seeded onto a 96-well
culture plate at a density of 5000 cells/well in 100 μl of
complete DMEM. On the second day of culture, the cells
were then serum-deprived for 20 h prior to drug treat-
ment. Quiescent cells were then exposed to media con-
taining 10% FBS with LY294002 at a concentration of
3.125, 6.25, 12.5, 25 and 50 μM for 48 h. The cell number
was examined by MTT assay in triplicates. The inhibitorJournal of Experimental & Clinical Cancer Research 2009, 28:154 http://www.jeccr.com/content/28/1/154
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was dissolved in DMSO to a stock concentration of 50
mM and DMSO served as a solvent control and did not
affect cell proliferation. The assays were repeated three
times, and the concentrations of LY294002 giving the
IC50 were determined.
Detection of the expression of Lewis y with 
immunocytochemical staining
The cells were seeded on the coverslips and fixed by 4% of
paraformalclehyde, then stained according to the SABC
test kit instructions. In brief, after blocking with goat
serum for 1 h at 37°C, the mouse anti-human Lewis y
antibody (1:100) was applied to incubate with the slide
overnight at 4°C. Lewis y immunostaining was performed
by avidin-biotin peroxidase complex kit and then photo-
graphed, where the existence of brownish yellow granules
in cytoplasm and cell membrane would be considered as
positive result.
Western immunoblotting
After various treatments, cells were washed twice with ice-
cold PBS, scraped in lysis buffer [50 mM Tris-HCl (pH
7.4), 150 mM NaCl, 0.5% NP40, 100 mM NaF, 200 μM
Na3VO4, and 10 μg/ml each aprotinin, leupeptin, PMSF,
and pepstatin], and incubated for 20 min at 4°C while
rocking. Lysates were cleared by centrifugation (15 min at
13,000 rpm, 4°C). For immunoblot analysis, 50 μg of
total protein were resolved by SDS-PAGE and transferred
to poly(vinylidene difluoride) membranes. Membranes
were blocked with TTBS [25 mM Tris-HCl, 150 mM NaCl
(pH 7.5), and 0.1% Tween 20] containing 5% nonfat milk
and incubated overnight at 4°C with primary antibody in
TBST/1% nonfat milk. Blots were washed in TTBS and
incubated with the appropriate horseradish peroxi-
daselinked IgG, and immunoreactive proteins were visu-
alized with ECL detection system.
In the treatment of PI3K inhibitor LY294002 and anti-
Lewis y antibody, the cells were subcultured for 72 h in
serum-containing medium and then serum-deprived for
20 h, and then treated with 25 μM of LY294002 or treated
with 20 μg/ml anti-Lewis y antibody for 24 h, and then
the cells were harvested for immunoblot analysis.
Statistical analysis
The SPSS 12.0 statistical analysis software was used, while
the analysis of variance was employed. p  < 0.05 was
regarded as with statistical significance.
Results
Characterization of α1,2-FT-transfected cell lines
The expressions of α1,2-FT mRNA in the pre- and post-
transfection cell lines were measured by RT-PCR. Results
showed that its expression of the post-transfection cell
line RMG-I-H was significantly higher than those of RMG-
I and RMG-I-pcDNA3.1 (Fig. 1A). Relative density analy-
sis of α1,2-FT mRNA expression vs. their internal control
β-actin expression indicated α1,2-FT mRNA expression in
RMG-I-H was increased 2.07-fold with RMG-I and 2.23-
fold with RMG-I-pcDNA3.1 (p < 0.01) (Fig. 1B). Further-
more, immunocytochemical staining revealed that the
expression of Lewis y, the product of α1,2-FT, was also
increased in RMG-I-H cells than that in RMG-I and RMG-
I-pcDNA3.1 cells. The expression of Lewis y was mainly
located on the cell surface (Fig. 1C).
Lewis y overexpression promotes cell proliferation
Lewis y overexpression significantly increased cell prolif-
eration in culture as examined by MTT assay (Fig. 2). The
proliferation rate of the post-transfection cells, RMG-I-H,
was much higher than the non-transfected group and the
group of transfected vector alone (p < 0.05). Also, there
was no significance difference between the RMG-I and
RMG-I-pcDNA3.1 (p > 0.05).
α-L-fucosidase inhibits cell proliferation
Immunocytochemical staining technique was used to
observe the expression of Lewis y in the cell lines before
and after the process by α-L-fucosidase. As shown in Fig.
1C, the cytoplasm and cell membrane of RMG-I-H-A and
RMG-I-A were without stains after the process by α-L-
fucosidase, whereas, the cytoplasm and cell membrane of
RMG-I-H did appear to have evenly distributed brownish
yellow granules, while the RMG-I was very lightly stained.
The proliferation of the cells before and after the process
by α-L-fucosidase was examined by MTT assay, as shown
in Fig. 3A, the cell growth rates of the experimental group,
RMG-I-H-A and RMG-I-A, were much lower than the con-
trol group, RMG-I-H and RMG-I, after the process by α-L-
fucosidase (p < 0.01). There was no significant difference
between RMG-I-H-A and RMG-I-A (p > 0.05), while the
proliferation rate of RMG-I was still lower than that of
RMG-I-H (p < 0.05). Colony formation test showed that
the cells, after processed by α-L-fucosidase, were mostly
single, the number of colony formation was much less
and the size of colony was also smaller. The colony forma-
tion rates of RMG-I-H-A and RMG-I-A cells were 11% and
13%, respectively. While, the colony formation rates of
RMG-I-H and RMG-I were 47% and 34%, respectively,
which were significantly higher than those of the experi-
mental group (p < 0.01) (Fig. 3B).
Anti-Lewis y antibody inhibits the proliferation of Lewis y-
overexpressing cells
Results in Fig. 4 showed that the cell growth of RMG-I-H
cells was markedly inhibited by anti-Lewis y antibody,
when compared with the control group RMG-I-H-C cells
at the different time (p < 0.05). However, no significant
difference in proliferation was found between RMG-I-aJournal of Experimental & Clinical Cancer Research 2009, 28:154 http://www.jeccr.com/content/28/1/154
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Characterization of α1,2-FT-transfected cell lines Figure 1
Characterization of α1,2-FT-transfected cell lines. (A) RT-PCR profiles of α1,2-FT mRNA in non- and α1,2-FT-trans-
fected cells. M: DNA ladder marker (100-2000 bp). (B) Relative expression of α1,2-FT mRNA in non- and α1,2-FT-transfected 
cells (n = 3). The data was expressed as the intensity ratio of α1,2-FT to β-actin (Mean ± SD). * p < 0.01 compared to the con-
trol. "A" is the representative of three independent and reproducible experiments. (C) Immunohistochemical staining for Lewis 
y antigen. (a) RMG-I-H cells; (b) RMG-I-pcDNA3.1 cells; (c) RMG-I cells; (d) RMG-I-H-A cells; (e) RMG-I-A cells. Meanwhile, a, 
b and c represents cells without α-L-fucosidase treatmeant; d and e represents cells with α-L-fucosidase treatmeant.
A 
 
 
B 
 
 
 
 
 
C 
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and RMG-I-C cells (p > 0.05). Meanwhile, the results in
Fig. 4 also show that the proliferation rate of RMG-I was
still lower than that of RMG-I-H (p < 0.05).
LY294002 inhibits the proliferation of Lewis y-
overexpressing cells
In order to investigate the mechanism of Lewis y-
enhanced cell growth, we use the inhibitor of PI3K,
LY294002, to treat the non- and α1,2-FT transfected cells,
then the cell proliferation was observed. Results in Fig. 5
showed that when RMG-I-H cells were incubated with
LY294002 at a concentration of 3.125, 6.25, 12.5, 25 and
50 μM for 48 h, respectively, the cell proliferation was
inhibited, especially at the concentration of 25 and 50
μM, the number of proliferated cells was decreased signif-
icantly, the concentrations of LY294002 giving the half
survival rates (IC50) were 23.18 ± 1.41 μM for RMG-I-H.
In contrast, the proliferation of RMG-I cells was not signif-
icantly affected by treatment with various concentrations
of LY294002.
PI3K/Akt signaling is required for Lewis y-enhanced growth 
of RMG-I cells
In grow factor signaling, activation of Akt has been impli-
cated as a key step. As shown in Fig. 6A, B, expression of
Akt protein was not obviously altered in Lewis y-overex-
pressing cells, but the relative phosphorylation of Akt (cal-
culated from the ratio of the staining intensity of
phophorylated protein to unphosphorylated protein after
normalization with β-actin) was apparently upregulated
to 5.37-fold of the non-transfection value in α1,2-FT
transfected cells. Reults in Fig. 6A, B also show that when
the two cell lines were treated by 20 μg/ml anti-Lewis y
antibody or 25 μM LY294002 for 24 h (corresponding
untreated cells were used as the control), phosphorylation
of Akt was apparently decreased in non- and α1,2-FT
transfected cells. By contrast, differences in phosphoryla-
tion intensity for Akt among non- and α1,2-FT transfected
cell groups were attenuated in anti-Lewis y antibody- or
LY294002-treated cells. When the cells were treated by
anti-Lewis y antibody or LY294002, the rate of inhibition
of phosphorylation was correlated with expression of
Lewis y, which was Lewis y-highexpressing < Lewis y-
lowexpressing cells.
PCNA is a commonly used marker to detect cell prolifera-
tion [18]. The difference in PCNA expression among these
cells prepared as indicated above was also measured by
western blotting. As shown in Fig. 6C, D, the expression of
PCNA protein was significantly elevated to 3.64-fold of
the non-transfection value in α1,2-FT transfected cells.
Meanwhile, in the presence of anti-Lewis y antibody or
LY294002, expression of PCNA, and the differences in its
expression intensities among the two cell lines were also
decreased, and the inhibition rate was also correlated with
expression of Lewis y, which was Lewis y-highexpressing <
Lewis y-lowexpressing cells.
Discussion
Among the various post-translational modification reac-
tions involving proteins, glycosylation is the most com-
mon, nearly 50% of all proteins are thought to be
glycosylated [19]. Glycosylation reactions are catalyzed by
the actions of glycosyltransferases, sugar chains being
added to various complex carbohydrates [20]. An increas-
ing body of evidence indicates that sugar chains in glyco-
proteins are involved in the regulation of cellular
functions including cell-cell communication and signal
transduction [21-23]. Research shows that 75% of ovarian
cancers have varying degree of Lewis y overexpression,
and increased expression is associated with poor progno-
sis of patients [24]. In our previous study, we introduced
α1,2-FT gene into human ovarian cancer cell line RMG-I
through gene transfection and established cell model
overexpressing  α1,2-FT gene and Lewis y [8]. Here by
comparing cell proliferation status before and after trans-
fection, we found that cell proliferation after gene trans-
fection was accelerated. To further test the role of Lewis y
in ovarian cancer cell proliferation, we treat Lewis y-over-
expressing RMG-I-H ovarian cancer cells with α-L-fucosi-
dase for the first time, which reducing the content of
fucosylated antigens on cell surface. Through observing
biological behaviors of cell before and after α-L-fucosi-
dase treatment, we found the cell proliferation rate in
transfected group was significantly higher than that of α-
L-fucosidase-treatment group. Our preliminary study
proved that the lactose type I chain family of the original
RMG-I cells was primarily glycolipid, and they were
Lc4Cer, Lewis a, and Lewis b, whereas, H-1 instead had the
The growth curves of each group of cells before and after  the transfection Figure 2
The growth curves of each group of cells before and 
after the transfection.Journal of Experimental & Clinical Cancer Research 2009, 28:154 http://www.jeccr.com/content/28/1/154
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Effects of α-L-fucosidase on the proliferation of the cells before and after the transfection Figure 3
Effects of α-L-fucosidase on the proliferation of the cells before and after the transfection. (A) The cell growth 
curves of each group before and after the process by α-L-fucosidase (B) The colony formation rates of each group before and 
after the process by α-L-fucosidase. *p < 0.01 compared to the control.
A 
 
 
 
B 
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absolute domination in the successfully transfected cells.
For the glycolipids of the lactose type II chain family, such
as Lewis x, Lewis y, IV3NeuAc-nLc4Cer and NeuAc-LeX,
their concentrations were over 0.01 μg per milliliter of dry
cells; however, the glycolipids shown in the transfected
RMG-I-H cells were Lewis x and Lewis y. 42.6% of Lewis x
in the RMG-I-H was converted into Lewis y, which was in
much higher percentage than the 3.2% of the original
RMG-I cells. Although type I chain family H-1 had the
absolute domination in the transfected RMG-I-H cells, its
actual content was only 1/4 of the Lewis y [8]. These fur-
ther proved that the changes of biological behaviors of
RMG-I-H cells, such as enhancement of proliferation and
growth, as well as the worsening in the severity of malig-
nancy, all had to do with the increase in Lewis y antigen.
Blocking experiments with Lewis y specific monoclonal
antibody provided further evidence for its function.
The molecular mechanism by which Lewis y antigen
causes the malignancy of ovarian cancer cell have not
been completely understood. In previous studies, we
tested the differences in oncogene expression before and
after α1,2-FT gene transfection using gene chips technol-
ogy. Results showed that: there were 88 differentially
expressed genes after cell transfection, and altered genes
mainly involved these genes regulating cell proliferation,
signal transduction, transcription and so on [25]. Thus, it
is possible that Lewis y may be an important component
in signaling transduction pathway participating in signal
transduction inside cell and further promoting prolifera-
tion of ovarian cancer cells. Studies found that anti-Lewis
y antibodies (ABL364 and IGN311) blocked the activa-
tion of mitogen-activated protein kinase (MAPK) signal-
ing pathway in A431 cells and prevented cell proliferation
[26]. The MAPK signaling pathway has central roles in the
regulation of cell survival and proliferation and our exper-
imental results have further verified this conclusion. Our
study found that the tyrosine phosphorylation level of
MAPK after α1,2-FT gene transfection increased than that
of before transfection in ovarian carcinoma-derived RMG-
I cells (in press). In addition to MAPK pathway, the PI3K/
Akt pathway is another critical pathway involved in cell
survival and has been shown to be constitutivelsy active in
ovarian cancer cell lines [27,28]. However, little is known
about the relation of Lewis y and the PI3K/Akt pathway in
the development and management of ovarian cancer. In
an effort to understand the mechanism of action of Lewis
y, we focused on investigating its effect on the PI3K/Akt
pathway. In this study, we found the PI3K/Akt pathway
was aberrantly activited by Lewis y antigen and PI3K/Akt
pathway is necessary for Lewis y enhancing growth of
RMG-I cells. It was verified by (1) increased tyrosine phos-
phorylation of Akt in α1,2-FT transfected cells. (2) block-
age of cell surface Lewis y by anti-Lewis y antibody
resulted in significant attenuation of the phosphorylation
of Akt, as well as the difference in phosphorylation inten-
sity among two cell lines. (3) in the presence of PI3K
inhibitor LY294002, Lewis y no longer conferred a growth
advantage in RMG-I-H cell. One of the crucial down-
stream targets of PI3K is the serine/threonine kinase Akt.
Active Akt causes a variety of biological effects, including
suppression of apoptosis by phosphorylation and inacti-
vation of several targets along pro-apoptotic pathways. In
particular, activated Akt is able to phosphorylate a variety
of downstream substrates, e.g., Raf and I-K (a kinase that
regulates the NF-κB transcription factor) [29]. A number
of studies have demonstrated that the patients with
increased p-Akt had a significant survival disadvantage
compared to patients with lower Akt phosphorylation,
The cell growth curves of each group before and after the  process by anti-Lewis y antibody Figure 4
The cell growth curves of each group before and 
after the process by anti-Lewis y antibody.
The cell growth curves of each group before and after the  process of LY294002 Figure 5
The cell growth curves of each group before and 
after the process of LY294002.Journal of Experimental & Clinical Cancer Research 2009, 28:154 http://www.jeccr.com/content/28/1/154
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PI3K/Akt signaling is required for Lewis y-enhanced growth of RMG-I cells Figure 6
PI3K/Akt signaling is required for Lewis y-enhanced growth of RMG-I cells. (A) Western blot profiles of Akt and p-
Akt in non- and α1,2-FT transfected cells, as well as in the absence and presence of anti-Lewis y antibody and LY294002. (B) 
Densitometric quantification of protein expression of A (n = 3). (C) Western blot profiles of PCNA in non- and α1,2-FT trans-
fected cells, as well as in the absence and presence of anti-Lewis y antibody and LY294002. (D) Densitometric quantification of 
protein expression of C (n = 3).* p < 0.01 compared to RMG-I. # p < 0.01 compared to RMG-I-H cells without anti-Lewis y 
antibody or LY294002 treatment. "A" and "C" are the representative of three independent and reproducible experiments.
  A 
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C 
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and the patients with ovarian cancer suggested p-Akt over-
expression as an independent prognostic indicator [30-
32]. To our knowledge, this is the first report showing that
overexpression of Lewis y antigen could significantly
enhance proliferation of ovarian cancer cells through
upregulating PI3K/Akt pathway.
Lewis y is mainly distributed at the plasma membrane of
cancer cells [33], and carried by different glycolipids [34]
and glycoproteins, such as CD44v6 [35], Muc6 [36] and
epidermal growth factor receptor (EGFR) [37], which are
related to carcinogenesis. Studies showed that changes in
glycosyltransferase expression might affect structure of
carbohydrate chains on cell surface receptors and there-
fore impacted the expression and function of those glyco-
protein receptors [38,39]. It has been reported that
transfection of the sense cDNA of N-acetylglucosaminyl-
transferase(GnT)-V, an enzyme associated with cancer
progression and metastasis, into human H7721 hepato-
carcinoma cells resulted in an increase in the level of
GlcNAcβ1,6 Manα1,6-branch (GnT-V product) on the N-
glycans of EGFR, this promoted the tyrosine autophos-
phorylation of EGFR [40]. From the above we speculate
that there might be one possibility implicated in the
mechanism that Lewis y antigen activates PI3K pathway.
The over-expression of α1,2-FT cDNA results in the eleva-
tion of Lewis y content on some surface receptors, which
might alter the comformation of the receptors, then pro-
moting the signaling of the receptor and finally stimulat-
ing the proliferation of ovarian cancer cells. Our studies
have found that the total amount of surface Lewis y as well
as the Lewis y content on some surface receptors were all
increased, and Lewis y expression on EGFR was very high
on α1,2-FT-transfected cells (in press).
Cross-talk between the PI3K/Akt and the Raf/MEK/MAPK
signaling pathways has been implied in human various
malignant tumors, with some research stating that PI3K
activity is essential for induction of Raf/MEK/MAPK activ-
ity [41,42]. Additional studies suggest that the PI3K/Akt
pathway enhances and/or synergizes with Raf/MEK/
MAPK signaling to provide a more robust survival signal
[43]. We speculate whether such cross-talk between the
two pathways also exists in Lewis y-overexpressing ovar-
ian cancer cells, and whether Lewis y is the key point for
triggering or regulating this cross-talk, the detailed mech-
anism requires further study.
The changes in glycosyltransferase expression might affect
the sugar chain heterogeneity and distribution, which
may mask some tumor antigens, reduce the immuno-
genicity of tumor cells, and promote tumor cells immune
evasion. It has been confirmed that under normal circum-
stances, T lymphocytes do not recognize Lewis y antigen
[44]. This allows the evasion of tumor cells from the rec-
ognition and killing by the human immune system, in
order to easily enter the lymph nodes to form metastasis.
Other studies found a novel function for soluble Lewis y,
that is inducing cytokine release, such as interleukin-6 (IL-
6), through the Janus kinase 2 (JAK2) pathway [45,16].
We speculate that except for proliferation, Lewis y could
also induce tumor cells immune evasion through activat-
ing PI3K/Akt signaling pathway, the detailed mechanism
is being studied. Lewis y may participate in natural
humoral immune response, antibodies are ideally suited
for eradicating pathogens from bloodstream and early tis-
sue invasion. With regard to cancer cells, passively admin-
istered and vaccine induced antibodies have
accomplished this concept, limiting tumor cells and sys-
temic or intraperitoneal micrometastases in a variety of
preclinical models. Many protocols developing anti-Lewis
y vaccines have been performed [46,47].
In summary, we showed that increased expression of
Lewis y antigen plays an important role in promoting cell
proliferation through activating PI3K/Akt signaling path-
way in ovarian carcinoma-derived RMG-I cells. Inhibition
of Lewis y expression may provide a new therapeutic
approach for Lewis y positive ovarian cancer.
Conclusions
Lewis y overexpression promotes the proliferation of ovar-
ian carcinoma-derived RMG-I cells and the PI3K/Akt sign-
aling pathway is necessary for Lewis y-enhanced growth of
RMG-I cells. These results may contribute for the develop-
ment of a novel therapeutic methodology to treat Lewis y
positive cancers.
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